Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase

IMPORTANCE: In June 2020, the US Food and Drug Administration approved the anti–programmed cell death 1 drug pembrolizumab for patients with malignant solid tumors of any histologic type with high tumor mutational burden (TMB; ≥10 mutations per megabase). The predictive value of this universal cutof...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Oncol
Auteurs principaux: Valero, Cristina, Lee, Mark, Hoen, Douglas, Zehir, Ahmet, Berger, Michael F., Seshan, Venkatraman E., Chan, Timothy A., Morris, Luc G. T.
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2021
Sujets:
Brief Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7893543/
https://ncbi.nlm.nih.gov/pubmed/33599686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.7684
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires